There is some evidence in humans that the kidney protection of SGLT2 inhibitors is somewhat stronger in the presence of T2DM (Heerspink et al., 2021) and the mice in the current study were not diabetic. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.